Virginia M Kelly

Suggest Changes
Learn More
6535 Background: BOS is an orally active, dual Src/Abl tyrosine kinase inhibitor (TKI). METHODS This open-label, phase 1/2 trial evaluated safety and efficacy of BOS as 3rd-line therapy in patients(More)